Neurocrine Biosciences Competitive Intelligence & Landscape

Neurocrine Biosciences (neurocrine.com) is a pharmaceutical company dedicated to discovering and developing life-changing treatments for patients suffering from neurological, psychiatric, endocrine, and immunological disorders [neurocrine.com]. Founded in 1992 by Wylie Vale, Ph.D., and Lawrence Steinman, Ph.D., the company's mission is rooted in relieving suffering for people with significant unmet medical needs [neurocrine.com]. Their commitment to "Brave Science" reflects over three decades of unwavering dedication to scientific discovery [neurocrine.com].

The company's core focus is on developing treatments for rare and under-addressed diseases [neurocrine.com/about-us/].

Neurocrine Biosciences emphasizes that discovering and developing new medicines is just one part of their responsibility; they are also committed to ensuring patient access to these crucial medical advancements [neurocrine.com/our-responsibility/]. With more than 2,000 employees, Neurocrine Biosciences has grown significantly since its inception, while maintaining its purpose and values centered on underserved patients worldwide [neurocrine.com/about-us/].

Headquartered in San Diego, CA, a prominent biotech hub, Neurocrine Biosciences operates with a leadership team focused on delivering life-changing treatments [neurocrine.com/contact-us/, neurocrine.com/work-with-us/, neurocrine.com/leadership/]. The company's culture is described by its employees as caring, collaborative, fun, and supportive, embracing a casual West Coast vibe [neurocrine.com/meet-our-people/].

Neurocrine Biosciences (neurocrine.com) focuses on the development and commercialization of treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company's approach to pricing its medicines is value-based, aiming to ensure that important medical advancements are accessible to patients in need [neurocrine.com/our-responsibility/]. While specific pricing plans, tiers, or free vs. paid features are not explicitly detailed for individual products, the company provides information related to pricing transparency and affordability. For instance, Neurocrine Biosciences adheres to the Vermont “Pharmaceutical Marketer Price Disclosure Law,” which requires disclosure of drug prices to prescribers for their marketed products, including INGREZZA® (valbenazine) [neurocrine.com/investors/corporate-governance/].

The company's approved medicines in the U.S. include INGREZZA®, CRENESITY®, and VYKATXR®, with product information available on their respective dedicated websites [neurocrine.com/approved-medicines/]. While details on current pricing plans and any recent pricing changes for these specific medications are not published directly on neurocrine.com, the company does report on the percentage change in both weighted average list price and weighted average net price across its product portfolio [www.neurocrine.com/media/documents/FINAL_NBIX_2025_Corporate_Responsibility_Report.pdf]. This indicates an ongoing assessment of their pricing strategies and their commitment to affordability in their corporate responsibility reports.

Neurocrine Biosciences acknowledges the potential for pricing controls and coverage limitations on their products [www.neurocrine.com/documents/139/NBIX_Q1_2026_Earnings_Presentation_Final_05.05.26.pdf]. They continue to develop and commercialize treatments for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, endometriosis, and uterine fibroids, emphasizing their dedication to patients with unmet medical needs [www.neurocrine.com/media/documents/Neurocrine_2024-CSR-Report_04_TmA9ec0.10.24_Final_qKTBtRD.pdf]. Their investor relations section provides updates on corporate presentations and earnings, which may include discussions around product performance and market dynamics, indirectly touching upon pricing strategies [neurocrine.com/investors/].

Neurocrine Biosciences demonstrates a consistent and active approach to hiring, emphasizing its commitment to expanding its team to support its core mission of discovering life-changing treatments. The company actively encourages individuals who are passionate about "more oomph to science and more heart to healthcare" to explore career opportunities [neurocrine.com/work-with-us/]. This focus on a dedicated and driven workforce aligns with their stated purpose of relieving suffering for people with great needs through "Brave Science®" [neurocrine.com/].

The company's career pages highlight a robust recruitment drive, frequently directing prospective employees to "View All Opportunities" [neurocrine.com/work-with-us/]. This indicates a continuous need for talent across various roles, signaling growth and ongoing research and development efforts in neurological, psychiatric, endocrine, and immunological disorders [neurocrine.com/]. While specific job openings are not detailed in the provided content, the consistent call to action to view opportunities suggests a broad range of positions are regularly available, from scientific roles to support functions.

Neurocrine Biosciences also places a strong emphasis on fostering a positive and supportive work environment. They describe their culture as "caring, collaborative, fun, supportive, and a little bit weird," reflecting a casual West Coast vibe from their San Diego base [neurocrine.com/meet-our-people/]. This cultural emphasis, along with their commitment to equal opportunity without diversity hiring quotas, suggests a strategy to attract and retain talent by building an inclusive environment where every employee can make an impact based on their skills and contributions [neurocrine.com/belonging-respect-and-empowerment/]. There is no information in the provided sources to suggest any recent layoffs; instead, the overall sentiment points towards a company focused on growth and career development [neurocrine.com/work-with-us/].

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) demonstrates a robust financial position, driven by strong net sales and a durable cash flow profile. The company anticipates INGREZZA annual guidance of $2.7-2.8 billion in net sales for 2026, building on expected sales of over $2 billion for INGREZZA in 2024. Additionally, CRENESITY is projected to generate approximately $301 million in net sales in its first full year of sales by 2025 [neurocrine.com/documents/136/NBIX_2025_Annual_Report.pdf]. As of December 31, 2025, Neurocrine Biosciences reported substantial cash and investments, underscoring its strong balance sheet and attractive profit and loss profile, which positions the company for sustainable growth and value creation [neurocrine.com/documents/136/NBIX_2025_Annual_Report.pdf].

Neurocrine Biosciences has consistently focused on strengthening its financial foundation. In 2017, the company successfully raised over $500 million through a convertible debt offering, significantly bolstering its balance sheet and supporting the commercial launch of INGREZZA, the first FDA-approved treatment for tardive dyskinesia (TD) [neurocrine.com/media/documents/520757_COMBO_BOOK_BROADRIDGE.pdf]. This strategic financial move was pivotal in transforming Neurocrine into a commercial organization.

The company maintains transparency with its financial communications and investor relations, regularly hosting webcasts and presentations for stakeholders [neurocrine.com/investors/]. For instance, Neurocrine Biosciences was scheduled to present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026 [neurocrine.com/investors/]. The company’s commitment to scientific discovery, which spans over three decades, underpins its financial health and ongoing development of treatments for neurological, psychiatric, endocrine, and immunological disorders [neurocrine.com/].

Neurocrine Biosciences was founded in 1993 and has since focused on areas with unmet medical needs or limited treatment options [neurocrine.com/media/documents/2023Annual-Report_3vK5hGJ.pdf]. The company’s continued financial strength and strategic investments enable its mission of relieving suffering for people with significant medical needs [neurocrine.com/].

Neurocrine Biosciences actively engages in various events, including industry conferences, webcasts, and community initiatives [https://neurocrine.com/investors/webcasts-presentations/]. The company's management team frequently participates in industry conferences, delivering presentations on company updates and progress in research and development [https://neurocrine.com/investors/webcasts-presentations/]. These participations often include conference calls and webcasts, with replays typically available for up to 30 days after an event [https://neurocrine.com/investors/webcasts-presentations/].

For instance, Neurocrine Biosciences executives were scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026 [https://neurocrine.com/investors/]. The company also hosts regular conference calls to provide financial highlights and news updates [https://neurocrine.com/investors/webcasts-presentations/]. Detailed information regarding past and upcoming webcasts and presentations can be found on their investor relations page [https://neurocrine.com/investors/].

Beyond investor-focused events, Neurocrine Biosciences demonstrates a commitment to community and scientific advancement. The company supports patient organizations with financial backing to further their shared mission of relieving patient suffering and improving lives [https://neurocrine.com/neurocrine-biosciences-funding-support-request-portal/]. This includes memberships and sponsorships aimed at innovation and service to patients and caregivers [https://neurocrine.com/neurocrine-biosciences-funding-support-request-portal/].

Neurocrine Biosciences also champions awareness campaigns, such as its ongoing support for Tardive Dyskinesia (TD) Awareness Week, recognized during the first full week of May [https://neurocrine.com/td-awareness/]. This initiative focuses on reducing stigma and providing support for individuals affected by TD, emphasizing education and empowerment [https://neurocrine.com/td-awareness/]. Furthermore, the company offers an Early Career Investigator Award to support clinicians and basic scientists in endocrinology, enabling them to present their original work in adrenal research at events like ESPE or ECE [https://eu.neurocrine.com/NonUkResidents/HCP/awards/early-career-investigator-award].